BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 15729206)

  • 1. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacotherapy in ovarian carcinoma].
    Pfisterer J; Du Bois A
    MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
    Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
    Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of chemotherapy in the management of epithelial ovarian cancer.
    Reed NS; Sadozye AH
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):139-47. PubMed ID: 15757446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary chemotherapy in epithelial ovarian cancer.
    Hurwitz HI; McGuire WP
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):141-54. PubMed ID: 7912423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helical tomotherapy as a new treatment technique for whole abdominal irradiation.
    Rochet N; Sterzing F; Jensen A; Dinkel J; Herfarth K; Schubert K; Eichbaum M; Schneeweiss A; Sohn C; Debus J; Harms W
    Strahlenther Onkol; 2008 Mar; 184(3):145-9. PubMed ID: 18330510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
    Li GT
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
    Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
    Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
    Markman M
    Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis and management of epithelial ovarian cancer.
    Bhoola S; Hoskins WJ
    Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of chemotherapy in gynecologic cancer.
    Tropé C; Kristensen G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-1-S15-22. PubMed ID: 9346216
    [No Abstract]   [Full Text] [Related]  

  • 17. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 18. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
    Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
    Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.